Doripenem hydrate

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H341：유전적인 결함을 일으킬 것으로 의심됨 (노출되어도 생식세포 유전독성을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재)

• 예방조치문구

  P201：사용 전 취급 설명서를 확보하시오.

  P202：모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.

  P281：요구되는 개인 보호구를 착용하시오

  P308+P313：노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.

  P405：밀봉하여 저장하시오.

  P501：...에 내용물 / 용기를 폐기 하시오.

Doripenem hydrate 화학적 특성, 용도, 생산

• 개요

  Doripenem hydrate is a carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.
  Doripenem hydrate was first approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 25, 2005, then approved by the U.S. Food and Drug Administration (FDA) on Oct 12, 2007, and approved by European Medicines Agency (EMA) on July 25, 2008. It was developed by Shionogi and Janssen, then marketed as Finibax® in Japan and as Doribax® in the US by Shionogi and as Doribax® by Janssen in BE.

• 화학적 성질

  Doripenem Hydrate occurs as a white to pale yellow-brown-white crystalline powder. It is sparingly soluble in water, slightly soluble in methanol, and practically insoluble in ethanol (99.5). It is gradually colored to pale yellow-brown-white by light.

• 용도

  Doripenem (doripenem monohydrate) is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It is particularly active against Pseudomonas aeruginosa

• Biochem/physiol Actions

  Doripenem is an ultra-broad spectrum carbopenem antibiotic. Doripenem is active against both gram-positive and gram-negative bacteria.

Doripenem hydrate 공급 업체

Global(219)Suppliers

Doripenem hydrate 관련 검색